ICGN (Icagen)
All Pro Portfolios with ICGN
All Do-It-Yourself Portfolios with ICGN
- Total Do-It-Yourself Portfolios with ICGN:
- tom kriss Portfolio 1
- First One by JiMi G
- Tompsi Portfolio 1
- Hobby
- agressive buys
- SUPRATRADE XELLERON 8
- SUPRATRADE HOT WEDNESDAY "FAILING DOWN"
- Spec #1
- nelsus0508 Portfolio 1
- decaking
- baileyman2003 Portfolio 1
- Last Day of the JPMorgan Healtcare Conf.
- show more
- 24
- Penny stock Futures
- aal Portfolio 1
- PDELLER STOCKS
- 2/21/07a
- russellwalker@comcast.net Portfolio 1
- SUPRATRADE-QUANTUM "STAR TREK"
- profshan Portfolio 1
- stmedcastle Portfolio 1
- Betty McAlpin Portfolio 1
- bminato Portfolio 1
- PART 7 JPMorgan 26th Annual Healthcare Conf 1/10/08..4th Day Reporting Companies..Nymph Take
- Barron's Activist Stocks 9-12-2009
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:barrons3 |
Date:09 12 09 |
Xmark Opportunity Partners reduced its holdings to 3,793,465 shares (8.1%), after selling 243,500 from Aug. 3 to Aug. 27 at prices ranging from 83 cents to $1.06 per share. |
|
Not yet rated
Rate now:
|
|
Date:01 10 09 |
|
11 |
|
Not yet rated
Rate now:
|
|
By:katie7ch |
Date:07 01 08 |
Sodium Ion Channel Blocking medication underway to help develop a new drug for pain relief. Pain is a huge problem that costs American businesses tons of money. Backed by Pfizer. |
|
Not yet rated
Rate now:
|
|
Date:08 14 07 |
|
Just made a deal with Phizer for funding in research. |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Downgraded by JP Morgan from Overweight to Neutral |
|
Not yet rated
Rate now:
|
|
By:pmuru |
Date:03 22 07 |
insider buying and stock has been overly beaten up related to product pipe-line. |
|
Not yet rated
Rate now:
|
|
By:stouch |
Date:12 29 06 |
a biopharmaceutical company, engages in the discovery, development, and commercialization of orally-administered small molecule drugs that modulate ion channel targets. |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
| Comments not available |
